ONCOTHERAPEUTICS PLANS PHASE II OTx-287 STUDIES IN RENAL, COLORECTAL
Executive Summary
ONCOTHERAPEUTICS PLANS PHASE II OTx-287 STUDIES IN RENAL, COLORECTAL and either brain or melanoma cancers in the next 12 to 18 months, Exec VP-R&D Frank Pilkiewicz, PhD, told a Mabon Securities conference on cell therapy, gene therapy and drug delivery companies in New York City Feb. 16. Pilkiewicz described OTx-287 as a "proteo-liposome formulation" of interleukin-2. Recombinant IL-2 is marketed by Chiron for treatment of metasiatic renal cell carcinoma as Proleukin.